Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

188P - Integration of immunohistochemistry and transcriptomics reveals new insights into the immune landscape of soft-tissue sarcomas

Date

14 Sep 2024

Session

Poster session 08

Topics

Tumour Immunology

Tumour Site

Soft Tissue Sarcomas

Presenters

Giulia Petroni

Citation

Annals of Oncology (2024) 35 (suppl_2): S238-S308. 10.1016/annonc/annonc1576

Authors

F. Scolari1, E. Caliman2, R. Scanferla3, G. Scoccianti3, B. Menicacci1, A. Palomba4, F. Nozzoli4, D.A. Campanacci3, L. Antonuzzo5, S. Pillozzi1

Author affiliations

  • 1 Department Of Experimental And Clinical Biomedical Sciences 'mario Serio', University of Florence, 50134 - Firenze/IT
  • 2 Clinical Oncology Unit, Careggi University Hospital, Florence, Italy, 50134 - Florence/IT
  • 3 Department Of Orthopaedic Oncology And Reconstructive Surgery,, Careggi University Hospital, 50139 - Firenze/IT
  • 4 Histopathology And Molecular Diagnostic Unit, Careggi University Hospital, 50134 - Firenze/IT
  • 5 Department Of Experimental And Clinical Medicine, UniFI - Università degli Studi di Firenze, 50134 - Firenze/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 188P

Background

Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLS) and B cells. However, the cellular and molecular mechanisms underlying these clinical associations have not been elucidated yet.

Methods

TME composition and TLS quantification were assessed by sequential IHC with αCD3, αCD20, αCD23 and αCD68 antibodies on specimens obtained from patients with primary or locally recurrent STS enrolled and treated at the Careggi Hospital (RESEARCH study). TME transcriptomic profiling was performed using the nCounter Immunology Panel by NanoString. RNA-sequencing and clinical data for 206 STS patients were retrieved from the TCGA SARC project.

Results

IHC of 23 treatment-naïve STS specimens showed higher TLS density and incidence in the group of non-recurrent patients (11/15) compared to patients developing recurrence (2/8; P=0.039). CD8+ T cell, CD20+ B cell and CD23+ follicular dendritic cell densities are higher in the TME of TLS+ STS. CD20 and CD23 (but not CD8) expression is associated to improved recurrence-free survival (RFS) and overall survival (OS) in our cohort. Transcriptomic analysis of 31 treatment-naïve STSs showed that high expression of genes discriminating for germinal center (GC) B cells correlated to the upregulation of Th17-related genes, and decreased expression of M2-like tumor-associated macrophages (TAMs)-related genes. High expression of GC B cell- and Th17 differentiation-related signatures showed associations to longer RFS in our cohort, and to improved OS in the TCGA SARC cohort. Analysis of 5 samples obtained after neoadjuvant radiotherapy (RT) showed reduced expression of IL17A and GC B-related genes while increased TAM-related gene expression, compared to paired biopsies obtained before RT.

Conclusions

Our data identified a prognostic value for Th17-related genes, suggest a potential crosstalk between GC B cells and Th17 cells in coordinating antitumor immune responses, and a potential role for M2-like TAMs (and RT) in inhibiting TLS formation in STS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.